Veterinary Autoimmune Disease Therapeutics Market Analysis

Veterinary Auto-immune Therapeutics Market Analysis

Based on the type of therapy, the veterinary auto-immune therapeutics market is segmented into corticosteroids, azathioprine, cyclosporine, mycophenolate, leflunomide, cyclophosphamide, levothyroxine, folic acid, hydroxychloroquine, and chloroquine. Corticosteroids held the highest revenue of USD 1.1 billion in 2022 and expected to grow in the forecast period. Corticosteroids are potent anti-inflammatory agents. In veterinary medicine, many autoimmune conditions involve an excessive immune response and inflammation, leading to tissue damage. Corticosteroids help mitigate inflammation by suppressing the immune system's response, reducing the severity of symptoms, and providing relief to affected animals.
 

Based on diseases, the veterinary auto-immune therapeutics market is divided into hypothyroidism, pemphigus disease, canine lupus, auto-immune haemolytic anaemia, bullous pemphigoid, discoid lupus erythematosus, immune-related arthritis, and other diseases. In 2022, the hypothyroidism segment accounted for the largest share of 30.7% in the market. Hypothyroidism is most common in dogs but also develops rarely in other animals like cats, horses, and other companion animals.
 

Based on animal type, the veterinary auto-immune therapeutics market is subdivided into companion animals, livestock animals, and other animals. The companion animal segment is further subdivided into dogs, cats, horses, and other companion animals. The livestock animal segment is further subdivided into cattle, swine, poultry, sheep, and other livestock animals. The companion animal segment held the largest market share of 61.3% in 2022. The key factors supporting the growth of this segment are the rapidly increasing pet ownership, the high prevalence of zoonotic diseases, the increasing adoption of pet insurance, and the increasing need of diagnostics and adequate treatment.
 

Based on distribution channel, the veterinary auto-immune therapeutics market is classified into veterinary hospitals and veterinary clinics. Veterinary hospitals held the largest share of 57.7% in 2022 owing to the well-established facilities for treatment and availability of wide range of medications in hospitals. The increasing prevalence of zoonotic diseases, the growing need of diagnostics, the increasing visits to veterinary hospitals and clinics, and the increasing number of veterinary practitioners are the factors driving the market trends.
 

North America veterinary auto-immune therapeutics market accounted for significant revenue in 2022 and is expected to reach USD 2.2 billion in 2032 with a CAGR of 5.5% from 2023-2032. North America has a large population of companion animals, including dogs, cats, and horses. The bond between pet owners and pets is getting strong and pet owners are focusing on pet’s health. As more people consider their pets as family members, the demand for advanced veterinary care rises. Pet owners are increasingly seeking effective treatments for their animals’ autoimmune disorders, driving the demand for relevant therapeutics in the region